| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/17/2023 | 22.89% | Morgan Stanley | → $16 | Initiates Coverage On | → Equal-Weight |
| 08/10/2023 | 61.29% | Needham | $30 → $21 | Maintains | Buy |
| 07/18/2023 | 30.57% | UBS | $28 → $17 | Downgrades | Buy → Neutral |
| 07/17/2023 | 15.21% | Stephens & Co. | $26 → $15 | Downgrades | Overweight → Equal-Weight |
| 07/17/2023 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 07/13/2023 | 92.01% | Roth MKM | $40 → $25 | Maintains | Buy |
| 07/13/2023 | 68.97% | B. Riley Securities | $30 → $22 | Maintains | Buy |
| 07/13/2023 | 99.69% | Stephens & Co. | → $26 | Reiterates | Overweight → Overweight |
| 07/13/2023 | -23.2% | SVB Leerink | $30 → $10 | Downgrades | Outperform → Market Perform |
| 07/13/2023 | 130.41% | Needham | → $30 | Reiterates | Buy → Buy |
| 06/06/2023 | 115.05% | UBS | $26 → $28 | Maintains | Buy |
| 05/05/2023 | 130.41% | Needham | → $30 | Reinstates | → Buy |
| 04/21/2023 | 130.41% | Needham | → $30 | Reiterates | → Buy |
| 02/24/2023 | 130.41% | Needham | $28 → $30 | Maintains | Buy |
| 12/08/2022 | 130.41% | Keybanc | $40 → $30 | Maintains | Overweight |
| 11/16/2022 | 130.41% | B. Riley Securities | $55 → $30 | Maintains | Buy |
| 11/04/2022 | 115.05% | SVB Leerink | $45 → $28 | Maintains | Outperform |
| 11/04/2022 | 115.05% | Needham | $49 → $28 | Maintains | Buy |
| 11/04/2022 | 207.22% | Keybanc | $52 → $40 | Maintains | Overweight |
| 07/12/2022 | 222.58% | Needham | $41 → $42 | Maintains | Buy |
| 05/06/2022 | 214.9% | Needham | $45 → $41 | Maintains | Buy |
| 05/06/2022 | 299.39% | Keybanc | $92 → $52 | Maintains | Overweight |
| 05/02/2022 | 245.62% | SVB Leerink | $75 → $45 | Maintains | Outperform |
| 02/25/2022 | 245.62% | Needham | $93 → $45 | Maintains | Buy |
| 02/25/2022 | 606.61% | SVB Leerink | $75 → $92 | Maintains | Outperform |
| 01/19/2022 | 591.24% | Roth Capital | → $90 | Upgrades | Neutral → Buy |
| 11/05/2021 | 591.24% | Roth Capital | $78 → $90 | Downgrades | Buy → Neutral |
| 11/05/2021 | 614.29% | Needham | $79 → $93 | Maintains | Buy |
| 11/05/2021 | 606.61% | Keybanc | $75 → $92 | Maintains | Overweight |
| 10/26/2021 | 629.65% | BTIG | $80 → $95 | Maintains | Buy |
| 08/06/2021 | 499.08% | Roth Capital | $72 → $78 | Maintains | Buy |
| 08/06/2021 | 506.76% | Needham | $77 → $79 | Maintains | Buy |
| 07/16/2021 | 514.44% | BTIG | → $80 | Initiates Coverage On | → Buy |
| 05/05/2021 | 491.4% | Needham | $73 → $77 | Maintains | Buy |
| 03/15/2021 | 545.16% | UBS | → $84 | Initiates Coverage On | → Buy |
| 03/02/2021 | 460.68% | Needham | → $73 | Assumes | → Buy |
| 03/02/2021 | 476.04% | SVB Leerink | $50 → $75 | Maintains | Outperform |
| 02/10/2021 | 522.12% | B. Riley FBR | $69 → $81 | Maintains | Buy |
| 01/19/2021 | 476.04% | KeyBanc | $54 → $75 | Maintains | Overweight |
| 01/14/2021 | 453% | Roth Capital | $60 → $72 | Maintains | Buy |
| 11/10/2020 | 314.75% | Keybanc | → $54 | Initiates Coverage On | → Overweight |
| 11/06/2020 | 245.62% | Needham | $44 → $45 | Maintains | Buy |
| 08/24/2020 | 237.94% | Needham | $37 → $44 | Maintains | Buy |
| 08/07/2020 | 184.18% | Needham | $23 → $37 | Maintains | Buy |
| 05/08/2020 | 92.01% | SVB Leerink | $24 → $25 | Maintains | Outperform |
| 04/07/2020 | 84.33% | B. Riley Securities | → $24 | Maintains | Buy |
| 03/06/2020 | 76.65% | Needham | $22 → $23 | Maintains | Buy |
| 02/13/2020 | 84.33% | B. Riley Securities | $26 → $24 | Maintains | Buy |
| 01/13/2020 | 68.97% | Needham | $24 → $22 | Maintains | Buy |
| 07/01/2019 | 68.97% | Needham | → $22 | Reinstates | → Buy |
| 10/10/2018 | 68.97% | B. Riley Securities | → $22 | Initiates Coverage On | → Buy |
What is the target price for CryoPort (CYRX)?
The latest price target for CryoPort (NASDAQ: CYRX) was reported by Morgan Stanley on August 17, 2023. The analyst firm set a price target for $16.00 expecting CYRX to rise to within 12 months (a possible 22.89% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CryoPort (CYRX)?
The latest analyst rating for CryoPort (NASDAQ: CYRX) was provided by Morgan Stanley, and CryoPort initiated their equal-weight rating.
When is the next analyst rating going to be posted or updated for CryoPort (CYRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CryoPort, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CryoPort was filed on August 17, 2023 so you should expect the next rating to be made available sometime around August 17, 2024.
Is the Analyst Rating CryoPort (CYRX) correct?
While ratings are subjective and will change, the latest CryoPort (CYRX) rating was a initiated with a price target of $0.00 to $16.00. The current price CryoPort (CYRX) is trading at is $13.02, which is within the analyst's predicted range.